Tiziana Life Sciences (TLSA) announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer’s disease who was treated for three months with intranasal foralumab under an expanded access program. The microglial TSPO PET scan revealed a significant decrease in microglia activation, a key indicator of neuroinflammation associated with Alzheimer’s disease progression.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences announces results from study of nasal foralumab
- Tiziana Life Sciences Reports Positive Results from Nasal Foralumab Study in MS
- Tiziana Life Sciences Delays Annual Report Filing
- Tiziana Life Sciences Expands Phase 2 Trial for Intranasal Foralumab with UMass Dosing
- Tiziana Life Sciences announces UMass commences Phase 2 na-SPMS trial